Novo Nordisk A/S Slogs Through the Year
Novo Nordisk (NYSE: NVO) continues to slog through the year, dealing with losing exclusivity on hormone-replacement therapy Vagifem and pricing pressure. The year-over-year comparison for Vagifem will go away, but expect continued pricing pressure next year. Fortunately Novo Nordisk has an opportunity to launch semaglutide; that will likely end up being its top-selling drug, and should make up for the lower prices.
Metric
First 9 Months 2017
Source: Fool.com
Novo Nordisk A/S ADR Stock
€133.00
0.380%
The stock is one of the favorites of our community with 22 Buy predictions and 1 Sell predictions.
As a result the target price of 144 € shows a slightly positive potential of 8.27% compared to the current price of 133.0 € for Novo Nordisk A/S ADR.
